Safety and feasibility of Y90 radioembolization for cirrhosis-induced splenomegaly and thrombocytopenia: results from an investigational device exemption study
Key Points
Y90 radioembolization showed a favorable safety profile for patients with cirrhosis and thrombocytopenia.
The study included a cohort of patients experiencing splenomegaly, showing promising outcomes after intervention.
Assessment utilized an investigational device exemption approach to evaluate treatment effectiveness and safety.
Findings suggest that Y90 radioembolization could be a viable option in treating symptoms related to cirrhosis.
Safety and feasibility of Y90 radioembolization for cirrhosis-induced splenomegaly and thrombocytopenia: results from an investigational device exemption study | Synapse